General Information of Drug (ID: DM6OTGE)

Drug Name
L-783483 Drug Info
Synonyms F3MethylAA
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9935197
TTD Drug ID
DM6OTGE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bardoxolone methyl DMODA2X Mixed connective tissue disease 4A43.3 Phase 3 [4]
AD-5075 DM1SLJ9 Type-2 diabetes 5A11 Terminated [5]
2-chloro-5-nitro-N-phenylbenzamide DMUGQIV Discovery agent N.A. Investigative [6]
LG100754 DMEK4FY Discovery agent N.A. Investigative [7]
L-796449 DMWTGQM Discovery agent N.A. Investigative [8]
L-165461 DMKBSGN Discovery agent N.A. Investigative [8]
AD-5061 DM5WV13 Discovery agent N.A. Investigative [9]
TZD18 DMVCHOX Discovery agent N.A. Investigative [10]
(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid DM2REIN Discovery agent N.A. Investigative [11]
reglitazar DMQ3ER0 Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VTB-38543 DMNY3J0 Atopic dermatitis EA80 Phase 2 [13]
2-Propanol, Isopropanol DML5O0H Discovery agent N.A. Investigative [14]
desmosterol DMV8SUM Discovery agent N.A. Investigative [15]
WAY-214950 DM8ODI7 Discovery agent N.A. Investigative [16]
27-hydroxycholesterol DM2L6OZ Discovery agent N.A. Investigative [17]
22R-hydroxycholesterol DME8273 Discovery agent N.A. Investigative [18]
GSK-9772 DM4WS3R Discovery agent N.A. Investigative [19]
Riccardin C DM6MYGX Discovery agent N.A. Investigative [20]
2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione DMH76SO Discovery agent N.A. Investigative [21]
AZ12260493 DMQ5H2V Discovery agent N.A. Investigative [22]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GFT-505 DM7ZOAE Non-alcoholic steatohepatitis DB92.1 Phase 3 [23]
MBX-8025 DMNTCV4 Obesity 5B81 Phase 2/3 [24]
T3D-959 DMR3245 Alzheimer disease 8A20 Phase 2 [25]
T3D-959 DMR3245 Alzheimer disease 8A20 Phase 2 [26]
KD3010 DMNFDYE Metabolic disorder 5C50-5D2Z Phase 1 [27]
SAR351034 DM15PG9 Dyslipidemia 5C80-5C81 Phase 1 [28]
CER-002 DMLBKZV Dyslipidemia 5C80-5C81 Phase 1 [29]
PMID25416646-Compound-Figure5-C DM17FKL N. A. N. A. Patented [30]
GW-501516 DMPL2KM Type-1 diabetes 5A10 Discontinued in Phase 4 [31]
Sodelglitazar DMJ816F Hyperlipidaemia 5C80 Discontinued in Phase 2 [32]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US9073931, E2 DMK9FJG N. A. N. A. Patented [33]
BDBM50177019 DMEL28G N. A. N. A. Patented [34]
US9006244, E2b DMP0TBO N. A. N. A. Patented [35]
US9073931, E1 DM2Z43I N. A. N. A. Patented [33]
US9006244, E1 DMBF1C0 N. A. N. A. Patented [35]
BDBM50177012 DM52IQF N. A. N. A. Patented [34]
US9006244, E2a DMPDF9B N. A. N. A. Patented [35]
67S DMJL1MB N. A. N. A. Patented [34]
US9073931, E3 DMCYM8P N. A. N. A. Patented [33]
desmosterol DMV8SUM Discovery agent N.A. Investigative [15]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oxysterols receptor LXR-alpha (NR1H3) TTECBXN NR1H3_HUMAN Agonist [2]
Oxysterols receptor LXR-beta (NR1H2) TTXA6PH NR1H2_HUMAN Agonist [2]
Peroxisome proliferator-activated receptor delta (PPARD) TT2JWF6 PPARD_HUMAN Agonist [3]
PPAR-gamma messenger RNA (PPARG mRNA) TTT2SVW PPARG_HUMAN Agonist [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2688).
2 A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002 Jul;143(7):2548-58.
3 Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25.
4 A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol. 2000 Oct;14(10):1550-6.
5 Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95.
6 Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
7 The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2002 Apr 12;277(15):12503-6.
8 Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
9 A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
10 A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8.
11 Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
12 Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
15 Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26.
16 Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
17 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001 Oct 19;276(42):38378-87.
18 An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31.
19 Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65.
20 Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
21 Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61.
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 601).
23 Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
24 ClinicalTrials.gov (NCT00701883) Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol. U. S. National Institute of Health. 2008.
25 Phrma report (2013 Alzheimers disease)
26 T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016;51(1):123-38.
27 Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007.
28 Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
29 Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010 May; 30(5): 894-899.
30 PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
31 Lipid effects of peroxisome proliferator-activated receptor- agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.Arterioscler Thromb Vasc Biol.2012 Sep;32(9):2289-94.
32 Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.
33 Liver X receptor modulators. US9073931.
34 Piperazine derivatives as liver X receptor modulators. US10144715.
35 Liver X receptor modulators. US9006244.